LLY

1,008.2

-0.35%↓

JNJ

229.76

+0.06%↑

ABBV

210.92

+1.82%↑

UNH

397.57

-0.56%↓

AZN

185.49

-0.26%↓

LLY

1,008.2

-0.35%↓

JNJ

229.76

+0.06%↑

ABBV

210.92

+1.82%↑

UNH

397.57

-0.56%↓

AZN

185.49

-0.26%↓

LLY

1,008.2

-0.35%↓

JNJ

229.76

+0.06%↑

ABBV

210.92

+1.82%↑

UNH

397.57

-0.56%↓

AZN

185.49

-0.26%↓

LLY

1,008.2

-0.35%↓

JNJ

229.76

+0.06%↑

ABBV

210.92

+1.82%↑

UNH

397.57

-0.56%↓

AZN

185.49

-0.26%↓

LLY

1,008.2

-0.35%↓

JNJ

229.76

+0.06%↑

ABBV

210.92

+1.82%↑

UNH

397.57

-0.56%↓

AZN

185.49

-0.26%↓

Начало・Списък с акции・BioCryst Pharmaceuticals Inc

BioCryst Pharmaceuticals Inc

Отворен

СекторЗдравеопазване

9.6 0.95

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

9.48

Максимум

9.77

Ключови измерители
By Trading Economics
Приходи	-1.1B -722M
Продажби	-250M 156M
P/E Средно за сектора	7.603 51.415
EPS	0.141
Марж на печалбата	-461.478
Служители	435
EBITDA	-968M -702M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+154.89% upside

Дивиденти
By Dow Jones
Следващи печалби	3.08.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-157M 2.2B
Предишно отваряне	8.65
Предишно затваряне	9.6

Настроения в новините

By Acuity

20%

80%

45 / 346 Класиране в Healthcare

BioCryst Pharmaceuticals Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

13.05.2026 г., 22:54 ч. UTC

Печалби

Xero Lifts Annual Earnings 18%, Flags More Growth Ahead

13.05.2026 г., 23:51 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

13.05.2026 г., 23:51 ч. UTC

Пазарно говорене

Australian Consumer Spending Is Holding Up; RBA Watching -- Market Talk

13.05.2026 г., 23:45 ч. UTC

Пазарно говорене

Nikkei May Rise After Overnight U.S. Tech Gains -- Market Talk

13.05.2026 г., 23:45 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

13.05.2026 г., 23:17 ч. UTC

Печалби

Samsung Fire & Marine Insurance 1Q Net Profit Beat FactSet-Compiled Consensus

13.05.2026 г., 23:16 ч. UTC

Печалби

Samsung Fire & Marine Insurance 1Q Net KRW635.22B Vs. Net KRW609.03B >000810.SE

13.05.2026 г., 23:15 ч. UTC

Печалби

Samsung Fire & Marine Insurance 1Q Oper Pft KRW861.13B Vs. Pft KRW792.36B >000810.SE

13.05.2026 г., 23:14 ч. UTC

Печалби

Samsung Fire & Marine Insurance 1Q Rev KRW6.676T Vs. KRW6.106T >000810.SE

13.05.2026 г., 23:02 ч. UTC

Пазарно говорене

Печалби

Cisco Product Demand Climbing Even Without Hyperscalers -- Market Talk

13.05.2026 г., 22:59 ч. UTC

Пазарно говорене

Печалби

Cisco Boosted by Tech Infrastructure Upgrade Cycle -- Market Talk

13.05.2026 г., 22:24 ч. UTC

Печалби

Xero FY U.S. Organic Revenue Growth 30%>XRO.AU

13.05.2026 г., 22:23 ч. UTC

Печалби

Xero FY International Organic Revenue Growth 25%>XRO.AU

13.05.2026 г., 22:23 ч. UTC

Печалби

Xero FY International Revenue Growth 47%>XRO.AU

13.05.2026 г., 22:22 ч. UTC

Печалби

Xero FY Australia, New Zealand Revenue Up 18% on Year >XRO.AU

13.05.2026 г., 22:19 ч. UTC

Печалби

Xero FY Australia, New Zealand Revenue Up 17% in Constant Currency>XRO.AU

13.05.2026 г., 22:19 ч. UTC

Печалби

Xero FY Net Customer Additions 506,000 Vs. 254,000>XRO.AU

13.05.2026 г., 22:18 ч. UTC

Печалби

Xero FY Rule of 40: 48.5% Vs. 44.3%>XRO.AU

13.05.2026 г., 22:16 ч. UTC

Печалби

Xero: Ebitda Guidance Includes NZD55M of Incremental U.S. Brand Spend>XRO.AU

13.05.2026 г., 22:15 ч. UTC

Печалби

Xero Expects FY27 Adjusted Ebitda of NZD860M-NZD920M>XRO.AU

13.05.2026 г., 22:15 ч. UTC

Печалби

Xero Expects FY27 Operating Revenue of NZD3.62B-NZD3.73B>XRO.AU

13.05.2026 г., 22:13 ч. UTC

Печалби

Xero FY Operating Expenses 70.5% of Operating Revenue Vs. 71.8%>XRO.AU

13.05.2026 г., 22:12 ч. UTC

Печалби

Xero FY Free Cash Flow NZD554.0M Vs. NZD506.7M>XRO.AU

13.05.2026 г., 22:11 ч. UTC

Печалби

Xero FY Adjusted Ebitda NZD757.4M Vs. NZD641.8M>XRO.AU

13.05.2026 г., 22:11 ч. UTC

Печалби

Xero FY Ebitda NZD789.5M Vs. NZD638.5M>XRO.AU

13.05.2026 г., 22:10 ч. UTC

Печалби

Xero Did Not Declare a Dividend>XRO.AU

13.05.2026 г., 22:10 ч. UTC

Печалби

Xero FY Rev NZD2.75B Vs. NZD2.10B >XRO.AU

13.05.2026 г., 22:09 ч. UTC

Печалби

Xero FY Net NZD167.4M Vs. Net NZD227.8M >XRO.AU

13.05.2026 г., 22:00 ч. UTC

Печалби

Cisco to Shed Jobs for All-In AI Push -- Update

13.05.2026 г., 21:11 ч. UTC

Печалби

Cisco Earnings and Revenue Beat Estimates on Strong AI Demand. Its Shares Surge. -- Barrons.com

Сравнение с други в отрасъла

Ценова промяна

BioCryst Pharmaceuticals Inc Прогноза

Ценова цел

By TipRanks

154.89% нагоре

12-месечна прогноза

Среден 22.43 USD 154.89%

Висок 32 USD

Нисък 13 USD

Според 8 анализатори от Wall Street, предложили 12-месечна ценова цел за BioCryst Pharmaceuticals Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

8 ratings

Купи

Задържане

Продай

Според 8 анализатори, дали борсови рейтинги на BioCryst Pharmaceuticals Inc през последните 3 месеца.

Настроение

By Acuity

45 / 346 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно BioCryst Pharmaceuticals Inc

BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.